


Healthcare News Roundup: Drug Delivery
HSMN NewsFeed - 26 Jun 2006
NexMed Announces Termination of Alprox-TD Agreement With Schering AG and Provides Operational Update
NexMed Announces Termination of Alprox-TD Agreement With Schering AG and Provides Operational Update
HSMN NewsFeed - 25 May 2006
Agile Therapeutics Closes $12 Million Financing for Development of a Low Estrogen Dose Contraceptive Patch
Agile Therapeutics Closes $12 Million Financing for Development of a Low Estrogen Dose Contraceptive Patch
HSMN NewsFeed - 25 May 2006
pSivida Provides Update on BrachySil(TM) Liver Program: Expansion of Multicenter Clinical Trial
pSivida Provides Update on BrachySil(TM) Liver Program: Expansion of Multicenter Clinical Trial
HSMN NewsFeed - 23 May 2006
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
HSMN NewsFeed - 23 May 2006
Ventaira Announces Positive Scintigraphy Data with Next-Generation Pulmonary Drug Delivery Device
Ventaira Announces Positive Scintigraphy Data with Next-Generation Pulmonary Drug Delivery Device
HSMN NewsFeed - 10 May 2006
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
HSMN NewsFeed - 10 May 2006
Unigene Enters into Exclusive Distribution Agreement for Fortical(R) Nasal Spray in Israel
Unigene Enters into Exclusive Distribution Agreement for Fortical(R) Nasal Spray in Israel
HSMN NewsFeed - 9 May 2006
Norwood Abbey Highlights Needle-Free Drug Delivery System and Commercial Strategic Update
Norwood Abbey Highlights Needle-Free Drug Delivery System and Commercial Strategic Update
HSMN NewsFeed - 9 May 2006
Sontra Medical Introduces Generation 2.0 SonoPrep(R) Skin Permeation Device
Sontra Medical Introduces Generation 2.0 SonoPrep(R) Skin Permeation Device
HSMN NewsFeed - 5 May 2006
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
